ARCA biopharma Announces Additional Patent
19-Jan-2012
|
Source :
|
Visits : 8166
BROOMFIELD, Colo. - ARCA biopharma Inc. today announced that the US Patent and Trademark Office (USPTO) has issued a patent on methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient has a specific genotype – homozygous for the arginine 389 polymorphism in the beta-1 adrenergic receptor. The patent (USP# 8,093,286) entitled “Methods for Treatment with Bucindolol Based on Genetic Targeting,” provides intellectual property protection in the United States for this novel approach to treating patients with bucindolol.
“We are pleased with the USPTO’s issuance of this patent, which we believe extends our pharmacogenetic intellectual property protection around bucindolol,” said Michael R. Bristow, president and chief executive officer of ARCA. “This patent provides protection for the means to identify patients with a specific genotype, which, based on data from a prior Phase 3 clinical trial, we believe has more favorable cardiovascular responses to Gencaro as compared to the general population of patients with all genotypes. In a planned phase 3 clinical trial, we intend to evaluate bucindolol as a potential treatment for the prevention of atrial fibrillation in patients with this genotype, which we estimate is present in approximately 50% of the US general population. We believe an important benefit of a pharmacogenetic approach to drug development is the potential for extending a drug candidate’s potential period of commercial exclusivity, if regulatory approval is obtained.”
ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases.